Supply Chain Disruptions Affect 70% of Biosimilar Product Launches

Biosimilar manufacturers are facing significant obstacles related to supply chain disruptions, impacting the successful launch and market penetration of their products. Supply chain issues cause significant delays in the introduction of biosimilars to the market. A recent analysis indicates that supply chain complications affect 70% of biosimilar product launches. According to DrugPatentWatch.com, these disruptions present a major challenge for manufacturers striving to bring biosimilars to market efficiently. Overcoming these logistical hurdles is critical for biosimilar manufacturers.

Newsflash | Powered by GeneOnline AI
Date: April 15, 2025

Author

Mark Chiang